Hydroxyurea, a myelosuppressive agent that has been a standard treatment in sickle cell disease (SCD) for decades, remains effective over the long term in children with the disease, according to a ...

Of the 2,147 participants, 1,240 (58%) had used hydroxyurea; of those, the average time on hydroxyurea was 5.1 years, with 304 children aged eight or older on continuous hydroxyurea therapy.

SAN DIEGO -- Treatment with hydroxyurea led to more hematologic dose-limiting toxicities (DLTs) compared with placebo in patients with hemoglobin SC, a milder form of sickle cell disease (SCD), a ...

Of the 2,147 participants, 1,240 (58%) had used hydroxyurea; of those, the average time on hydroxyurea was 5.1 years, with 304 children aged eight or older on continuous hydroxyurea therapy.

Researchers have found in recent clinical trial conducted in India that combining thalidomide with hydroxyurea (HU) ...

MONDAY, April 21, 2025 (HealthDay News) -- An oral chemotherapy drug can safely and effectively manage sickle cell disease in children, a new study says. Children taking hydroxyurea had fewer ER ...

Every day since Sanodiya’s diagnosis, aside from the months she was pregnant with her two kids, she has been taking hydroxyurea pills, the most widely used oral drug for treating sickle cell ...

How does treatment with exa-cel compare to other treatment options for patients with sickle cell disease? Standard treatment options such as hydroxyurea help mitigate the severity of vaso-occlusive ...

Hydroxyurea remains effective over the long term among children with sickle cell disease, real-world data suggested. The average time on hydroxyurea was 5 years, with many children on the therapy ...

a milder form of sickle cell disease (SCD), a Ghanaian randomized phase II trial showed. Hematologic DLTs -- mostly mild and transient -- occurred in 33% of patients taking hydroxyurea compared ...